microdosing glp 1 results my honest glp-1 weight loss journey Microdosing GLP-1: What to Know

doi: 10.1111/j.1365-2982.2010.01554.x

Breakdown of the drug Even when stored properly, the medications stability cannot be guaranteed after the beyond-use date

The negative health consequences of obesity include an increased risk of a wide spectrum of diseases including type 2 diabetes (T2DM), other cardiovascular disease risk factors (e.g., hypertension and dyslipidemia), cardiovascular disease, thromboembolic events, musculoskeletal disorders, fatty liver, chronic kidney disease, certain cancers, mental health disorders, as well as sleep apnea, limited mobility, and diminished quality of life [[6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]]

Key Products: Orforglipron (Foundayo), is first oral GLP-1 receptor agonist developed by the company that can be taken at any time of day